# Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension

> **NCT02169752** · NA · TERMINATED · sponsor: **National Jewish Health** · enrollment: 7 (actual)

## Conditions studied

- Pre-Pulmonary Atrial Hypertension

## Interventions

- **DRUG:** Ambrisentan

## Key facts

- **NCT ID:** NCT02169752
- **Lead sponsor:** National Jewish Health
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-09
- **Primary completion:** 2017-05-25
- **Final completion:** 2017-05-25
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** PI left National Jewish Health
- **Last updated:** 2021-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02169752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02169752, "Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02169752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*